Histamine H4 Receptor Expression in Triple-negative Breast Cancer: An Exploratory Study

SPEISKY, DANIELA; TÁQUEZ DELGADO, MÓNICA A.; IOTTI, ALEJANDRO; NICOUD, MELISA B.; OSPITAL, IGNACIO A.; VIGOVICH, FÉLIX; DEZANZO, PABLO; ERNST, GLENDA; URIBURU, JUAN L.; MEDINA, VANINA A.

THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY : OFFICIAL JOURNAL OF THE HISTOCHEMISTRY SOCIETY.

HISTOCHEMICAL SOC INC

Año: 2022 vol. 70 p. 311 - 322

0022-1554

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype. There are neither universally accepted prognostic markers nor molecular targets related to TNBC. The histamine H4 receptor (H4R) has been characterized in TNBC experimental models, demonstrating its critical role in tumor development and progression. In this study, H4R expression was compared in breast cancer subtypes and correlated with clinical features using The Cancer Genome Atlas data (Pan-Cancer Atlas). The H4R status was further evaluated by immunohistochemistry in 30 TNBC human samples in relation to clinicopathological parameters. Results indicate that H4R was downregulated in basal-like/TNBC compared with luminal A and normal breast-like tumors. The higher expression of H4R was associated with improved progression-free and overall survival outcomes in basal-like/TNBC. H4R immunoreactivity was detected in about 70% of tumors, and its expression was positively correlated with the levels in the histologically normal peritumoral tissue. High H4R expression in peritumoral tissue correlated with reduced number of lymph node involvement and unifocal TNBC, while it was associated with increased patient survival. In conclusion, the H4R might represent a potential prognostic biomarker in TNBC. Further studies in large cohorts are needed to better understand the significance of H4R in breast cancer biology: